van Rossum AGJ, et al. - Experts compared the additive value of taxanes with dose-dense anthracycline-based chemotherapy for high-risk breast cancer. Patients with pT1-3, pN0-3 breast cancer were randomly divided (1:1) between six adjuvant cycles of doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 2 weeks (ddAC) and six cycles of docetaxel 75 mg/m2, doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 every 3 weeks (TAC). Findings suggested that recurrence-free survival (RFS) and overall survival (OS) did not differ significantly between 6 adjuvant cycles of ddAC and TAC in high-risk breast cancer patients during a median follow-up of 7 years. In ddAC-treated patients, anemia was more frequent and in TAC-treated patients, diarrhea and peripheral neuropathy were observed more often.